Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 4/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.64 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27344186 | 0.98 | ADORA2A (0.96) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| SCHEMBL12281655 | 0.96 | ADORA2A (0.92) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| SCHEMBL3029368 | 0.89 | ADORA2A (0.79) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| SCHEMBL30979893 | 0.87 | ADORA2A (0.77) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| SCHEMBL23760187 | 0.83 | ADORA2A (0.71) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| SCHEMBL27758585 | 0.83 | ADORA2A (0.71) | ADORA2ANUDT1SCN9AMEN1KMT2A | |
| SCHEMBL29368486 | 0.83 | ADORA2A (1.00) | ADORA2ANUDT1SCN9AMAPTALDH1A1 | |
| SCHEMBL16614075 | 0.83 | ADORA2A (0.70) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| SCHEMBL17959853 | 0.82 | ADORA2A (0.69) | ADORA2ANUDT1SCN9A | |
| SCHEMBL24287260 | 0.82 | ADORA2A (0.73) | ADORA2ANUDT1SCN9ADCPSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106432205-A | Method for synthesizing lapatinib or intermediate thereof | 成都美睿科生物科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106316965-A | Quinazoline compound, intermediate thereof, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2017-01-11 | — | — | CN | claimed |
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | claimed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-20220177478-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK KGAA (DE) | 2022-06-09 | — | — | US | disclosed |
| US-11339132-B2 | Compound for organic electric element, organic electric element comprising the same, and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2022-05-24 | — | — | US | disclosed |
| US-20220029108-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, A PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2022-01-27 | — | — | US | disclosed |
| EP-3663283-B1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THIN FILM FORMED FROM THE COMPOSITION | SAMSUNG DISPLAY CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-20210198214-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2021-07-01 | — | — | US | disclosed |
| US-10934293-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2020187865-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2020-09-24 | — | — | WO | disclosed |
| US-10680183-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20080214586-A1 | 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators | MERCK PATENT GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| CN-101180278-A | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | CN | disclosed |
| CN-101180278-A | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | CN | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| CN-1229142-C | Compositions comprising NSAIDs and EFGR kinase inhibitors for the treatment or inhibition of colonic polyps and colorectal cancer | AMERICAN CYANAMID CO (US) | 2005-11-30 | — | — | CN | disclosed |
| CN-1370080-A | NSAID and EFGR kinase inhibitor contg. compsn. for treatment or inhibition of colonic polyps and colorectal cancer | AMERICAN CYANAMID CO (US) | 2002-09-18 | — | — | CN | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | ADORA2A 4510/4885NUDT1 2116/4885SCN9A 2504/4885 |
| US-20220177478-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | OR10J3, EPCAM, L1CAM | ADORA2A 3327/4885NUDT1 206/4885SCN9A 1272/4885 |
| US-10934293-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OPA1 | ADORA2A 4154/4885NUDT1 499/4885SCN9A 4284/4885 |
| US-10680183-B2 | Organic electroluminescent materials and devices | PNMT, CYCS, NES | ADORA2A 1546/4885NUDT1 1378/4885SCN9A 3519/4885 |
| US-20080214586-A1 | 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators | HSP90AB2P, HSP90AB1, HSP90AA1 | ADORA2A 2930/4885NUDT1 3458/4885SCN9A 3118/4885 |
| US-20210198214-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME, AND ELECTRONIC DEVICE THEREOF | PIEZO1, OCIAD1, OR10J3 | ADORA2A 4777/4885NUDT1 1905/4885SCN9A 321/4885 |
| US-11339132-B2 | Compound for organic electric element, organic electric element comprising the same, and electronic device thereof | PIEZO1, OCIAD1, OR10J3 | ADORA2A 4777/4885NUDT1 1905/4885SCN9A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.